Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to “Buy” at StockNews.com

StockNews.com cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a report published on Monday.

Several other brokerages also recently weighed in on REGN. Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Stock Down 1.5 %

REGN stock opened at $816.65 on Monday. The company has a market capitalization of $90.03 billion, a P/E ratio of 20.21, a price-to-earnings-growth ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals has a 12 month low of $783.57 and a 12 month high of $1,211.20. The firm’s fifty day simple moving average is $1,035.92 and its 200-day simple moving average is $1,038.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.